1stOncology™: Cancer Intelligence Service – Page 67 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

On May 29, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) reported that at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company’s next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People’s Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.

The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.

In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.

Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).

Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.

The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.

Professor Qing Zhou, principal investigator from Guangdong Provincial People’s Hospital, said: "From the first presentation of Phase I data at ASCO (Free ASCO Whitepaper) 2023 to today’s pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."

About lunbotinib fumarate (A400/EP0031, 宁泰莱)

Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.

In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.

(Press release, Kelun, MAY 29, 2026, View Source [SID1234666219])

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

On May 29, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) reported that at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱) in combination with pembrolizumab (KEYTRUDA[1], MSD’s anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East Hospital, Tongji University (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).

Sac-TMT is designed with a unique, bifunctional linker and differentiated belotecan-derivative payload. The linker is conjugated via cysteine, which maximizes payload delivery to tumor cells both through its irreversible connection with the high-affinity and targeting anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a moderately toxic novel topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4.

In the OptiTROP-Lung05 study, a total of 413 patients were randomized (1:1) to receive either sac-TMT in combination with pembrolizumab or pembrolizumab monotherapy.

As of the data cutoff date (September 29, 2025), with a median follow‑up of 10.5 months, the study demonstrated that:

Progression-free survival (PFS) showed statistically significant and clinically meaningful benefit in sac-TMT plus pembrolizumab compared with pembrolizumab alone. The median PFS assessed by blinded independent central review (BICR) was not reached (NR) vs 5.7 months (HR=0.35; 95% CI: 0.26-0.47; p<0.0001). The 12-month PFS rate was 62.4% vs 29.0%.
Consistent benefit across prespecified subgroups: In patients with PD‑L1 TPS ≥50% and TPS 1–49%, the PFS HRs were 0.47 (95% CI: 0.29–0.77) and 0.28 (95% CI: 0.19–0.41), respectively. In patients with non‑squamous and squamous NSCLC, the PFS HRs were 0.28 (95% CI: 0.18–0.43) and 0.44 (95% CI: 0.29–0.66), respectively.
Overall survival (OS) was not yet mature but showed a positive trend: median OS was NR vs 14.5 months (HR = 0.55; 95% CI: 0.36–0.85). The 12‑month OS rate was 80.4% vs 68.9%.
The combination group showed improvements over pembrolizumab monotherapy group in objective response rate (ORR) (70.2% vs 42.0%), deep response rate (49.0% vs 25.9%), and 12-month duration of response rate (77.7% vs 59.4%).
The incidence of grade ≥3 treatment-emergent adverse events (TEAEs) was higher in the combination group, primarily driven by the expected hematologic adverse events of sac-TMT. Incidence of discontinuation of pembrolizumab due to TEAEs was similar in both groups. No sac-TMT-related deaths occurred. Adverse events of special interest (AEOSIs) were consistent with the known safety profiles of each individual agent, and no new safety signals were identified.

The interim analysis results show that sac-TMT plus pembrolizumab significantly prolonged PFS and reduced the risk of disease progression or death compared with pembrolizumab alone, with consistent PFS benefits observed across all prespecified subgroups (including PD‑L1 expression levels and histological subtypes). A positive trend in OS was also observed. Furthermore, the overall safety profile of sac-TMT in combination with pembrolizumab was manageable, consistent with the established safety profiles of sac-TMT alone or pembrolizumab alone.

Notably, the findings of OptiTROP-Lung05 have been simultaneously published in The Lancet（Impact Factor=88.5）, indicating that its clinical and academic value has received dual recognition from a leading international academic conference and an authoritative journal.

Professor Caicun Zhou, the national leading principal investigator from Shanghai East Hospital, Tongji University, said: "The positive results of the OptiTROP‑Lung05 study are encouraging. The study not only supports the application of sac‑TMT in an earlier-line setting for lung cancer, but also provides evidence of the ‘ADC+IO’ synergistic strategy being evaluated in the first-line setting for PD‑L1‑positive advanced NSCLC, potentially bringing a new option to a broad population of patients with lung cancer."

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the National Medical Products Administration (NMPA).

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

(Press release, Kelun, MAY 29, 2026, View Source [SID1234666216])

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

On May 29, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported it will provide a program update on its first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400, highlighting new data that will be showcased across three presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. Two of the presentations showcase ATNM-400’s differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third demonstrates the importance of radioconjugate optimization for radiotherapies in the context of the Company’s pipeline candidates.

With the SNMMI 2026 program now finalized, the Company is providing updated presentation details, including poster titles, presenters, dates, and times. The data to be presented reinforce the meaningful progress of the ATNM-400 program and its potential as a mutation-agnostic, pan-tumor therapy, while also demonstrating the strength of the underlying radioconjugate platform that supports Actinium’s broader pipeline. The Company anticipates multiple catalysts for ATNM-400, Actimab-A and Iomab-ACT in 2H:2026 that are expected to demonstrate the clinical potential of these programs.

ATNM-400 SNMMI 2026 Presentation Details

Poster Title: ATNM-400: A First-in-Class Non-PSMA Actinium-225 Antibody Radioconjugate Demonstrates Superior Efficacy to PSMA-617 Radioligands and ARPIs With Favorable Safety Profile in Prostate Cancer Models
Presenter: Sumit Mukherjee Ph.D., Actinium Pharmaceuticals, Inc.
Session: Oncology: Discovery & Translational Meet the Author Session
Date & Time: Tuesday, June 2, 2026 11:30am-12:15pm PT | Los Angeles, California

Poster Title: ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer Models
Presenter: Shiva Kazerounian Ph.D., Actinium Pharmaceuticals, Inc.
Session: Oncology: Discovery & Translational Meet the Author Session
Date & Time: Tuesday, June 2, 2026, 11:30am-12:15pm PT | Los Angeles, California

Poster Title: Optimizing Chelator-to-Antibody Ratio Improves Tumor Targeting and Pharmacokinetics of 225Ac-Labeled Antibodies
Presenter: Shiva Kazerounian Ph.D., Actinium Pharmaceuticals, Inc.
Session: MTA05 RPSC/CMIIT POPs and Science Pavilion Mixer
Date & Time: Sunday, May 31, 2026, 7:30-8:00pm PT | Los Angeles, California

The posters will be available on the Company website shortly after the presentations at View Source

NYSE American Continued Listing Standards Notice
Actinium also announced today that it has received a notice (the "Notice") from the NYSE American LLC ("NYSE American") indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide"), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately $2.3 million and had net losses in its last five fiscal years ended December 31, 2025. The Notice also indicates that the Company is also not currently eligible for any exemption in Section 1003(a) of the Company Guide. The notice has no immediate effect on the listing or trading of the Company’s common stock on the NYSE American and the Company’s shares will continue to trade under the symbol "ATNM," subject to compliance with other listing requirements of the Company Guide.

In connection with the non-compliance with Sections 1003(a)(ii) and (iii) of the Company Guide, the Company must submit a compliance plan by June 26, 2026, advising of actions the Company has taken or will take to regain compliance with the continued listing standards by November 27, 2027 (the "Plan Period Deadline"). If the NYSE American determines to accept the plan, the Company will be notified in writing and will be subject to periodic reviews, including quarterly monitoring, for compliance with the plan.

If the Company does not submit a plan or if the plan is not accepted, delisting proceedings will commence. Furthermore, if the plan is accepted but the Company is not in compliance with the continued listing standards by the Plan Period Deadline which is eighteen months from the receipt of the notice or November 27, 2027, or if the Company does not make progress consistent with the plan during the plan period, Exchange staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

Actinium currently intends to submit a plan to regain compliance within the required timeframe. There can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required timeframe of eighteen months from date of receipt of the notice or November 27, 2027.

(Press release, Actinium Pharmaceuticals, MAY 29, 2026, View Source [SID1234666206])

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

On May 29, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported that the Canadian Intellectual Property Office (CIPO) has issued Notices of Allowance for two patent applications spanning the Company’s Actimab-A and Iomab-ACT programs. The allowances broaden Actinium’s intellectual property protection across both hematologic malignancies and next-generation conditioning for gene-edited cell-based therapies in Canada, an important market within the Company’s growing global patent estate. These Canadian allowances build on protection already secured in other major markets, including a previously granted Japanese patent for the Actimab-A program and an issued U.S. patent for the Iomab-ACT program, with additional applications pending in the United States, Europe and China.

The Notices of Allowance follow examination by CIPO, with issuance of the patents expected in the ordinary course. The allowances deepen Actinium’s intellectual property protection across two of its priority franchises and reinforce a global patent estate of approximately 250 issued and pending patents and patent applications.

"These two allowances reflect the breadth and depth of the innovation across our radiotherapy platform and our commitment to protecting it in every key market," said Adeela Kamal, Ph.D., EVP-R&D of Actinium Pharmaceuticals. "Securing coverage for both our Actimab-A CLAG-M combination in AML and our Iomab-ACT conditioning approach for gene-edited cell-based therapies underscores the strength of our science and the durability of the franchises we are building. We will continue to expand and defend our intellectual property worldwide as we advance these programs toward patients."

Actimab-A + CLAG-M Combination for AML

The allowed application covers the use of Actimab-A in combination with the CLAG-M chemotherapy regimen for the treatment of AML. Actimab-A is one of Actinium’s most advanced clinical-stage candidates and may serve as a therapeutic backbone for myeloid malignancies. The Canadian allowance complements a counterpart patent already granted in Japan, with applications pending in the United States and Europe. The Canadian patent issuing from Application No. 3,087,346 titled "Combination Immunotherapy and Chemotherapy for the Treatment of a Hematological Malignancy" will have a patent term running into January 2039.

Iomab-ACT for Gene-Edited Cell-Based Therapies

The allowed application covers Actinium’s targeted CD45 conditioning approach used to prepare patients for gene-edited cell-based therapies. Iomab-ACT is designed as a targeted conditioning agent intended to enable adoptive cell therapies. The Canadian allowance builds on a patent already granted in the United States, with additional applications pending in the United States, Europe and China. The Canadian patent issuing from Application No. 3,078,963 titled "Anti-CD45-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell-Based Therapies" will have a patent term running into October 2038.

(Press release, Actinium Pharmaceuticals, MAY 29, 2026, View Source [SID1234666205])

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

On May 29, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the ASCO (Free ASCO Whitepaper) Annual Meeting, conclude that the Prosigna Breast Risk of Recurrence (ROR) test safely guides adjuvant chemotherapy decisions in patients with early-stage, ER-positive HER2-negative breast cancer.

"Behind every breast cancer treatment decision is a patient asking, ‘Do I really need chemotherapy?’" said Prof. Robert Stein, Lead Investigator, University College London. "OPTIMA answers this question with robust evidence. These study results can be practice-changing – we can now use the Prosigna test to predict which high-risk patients can safely avoid chemotherapy and its lasting side effects without compromising outcomes. That is a profound shift for patients and the clinicians who care for them."

The Phase III prospective, randomized controlled trial compared standard of care – chemotherapy followed by hormone therapy – to treatment guided by Prosigna test results: patients with high ROR scores (>60) received chemotherapy followed by hormone therapy while those with low ROR scores (≤60) received hormone therapy alone.

Key Trial Findings

The OPTIMA trial results demonstrate:

Chemotherapy can be safely avoided for many patients: The Prosigna test identified that 68% of patients with clinically high-risk node-positive breast cancer, who previously would have received chemotherapy, could safely forgo it entirely. These patients achieved 5-year cancer-free survival rates of 93.7% — statistically noninferior to the 94.9% achieved with chemotherapy — demonstrating that omitting treatment for these patients does not compromise outcomes or increase recurrence risk.
Robust results across broadest range of high-risk subgroups: Non-inferiority was confirmed in previously under-studied populations where treatment guidance has been most uncertain, demonstrating that tumor biology, vs clinical factors alone, can guide chemotherapy decisions for:
Premenopausal women treated with ovarian function suppression (HR 1.04; 90% CI 0.60–1.80)
Patients with extensive nodal involvement (4–9 positive nodes, or pN2 disease) (HR 1.19; 95% CI 0.62–2.29)
Highest level of prospective evidence: With 4,429 patients and 4.0-year median follow-up, OPTIMA provides Level 1A evidence, showing that the Prosigna test can accurately predict chemotherapy benefit and guide safe de-escalation across patient populations.
The Impact on Patients with Breast Cancer

Breast cancer remains the most commonly diagnosed cancer worldwide, affecting 1 in 8 women in the U.S.,1 with over 225,000 new HR+/HER2- breast cancer cases diagnosed annually.2 Treatment decisions play a critical role in preventing recurrence and improving long-term outcomes.

For many of these patients, chemotherapy decisions have historically been driven by clinical factors alone – age, tumor size, and lymph node status – and its potential for multiple, severe side effects. Up to 43% of breast cancer survivors experience persistent nerve damage years after chemotherapy, with studies showing a broader range of treatment-related side effects impacting the majority of patients during and after care.3

The Prosigna test is a genomic test that uniquely combines intrinsic subtypes and proliferation score with clinical pathological factors to calculate a patient’s Risk of Recurrence (ROR) score. In OPTIMA, an ROR score < 60 enabled clinicians to identify patients who could safely avoid chemotherapy. The results from the OPTIMA trial are in a position to transform how clinicians approach breast cancer treatment decisions using the Prosigna ROR score to confidently de-escalate therapy in a high percentage of high-risk patients.

"OPTIMA sets a new standard for how chemotherapy decisions are made in breast cancer," said Phillip Febbo, M.D., Chief Scientific and Medical Officer, Veracyte. "Prosigna now has the strongest prospective evidence of any genomic test to predict which patients with clinically high-risk hormone-receptor positive breast cancer can safely avoid chemotherapy. For patients, that means the option to choose a treatment with fewer unnecessary side effects, and for clinicians, the confidence to act on it."

ASCO Annual Meeting Presentation

The OPTIMA trial results are being presented this Saturday, May 30 at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting during the Breast Cancer—Local/Regional/Adjuvant Oral Abstract Session (1:15 PM CDT, Hall B1, Abstract 500). Prof. Robert C. Stein from University College London is presenting the findings, which will also be livestreamed via the ASCO (Free ASCO Whitepaper) conference platform.

About the OPTIMA Trial

OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) is an international, multicenter randomized controlled trial led by University College London and funded by U.K. National Institute for Health and Care Research. The independent study enrolled 4,429 women and men aged ≥40 years with ER-positive HER2-negative early breast cancer and 0–9 involved axillary lymph nodes. Participants were randomly assigned to either the control arm for standard chemotherapy followed by hormone therapy or to the Prosigna test-directed arm of standard chemotherapy followed by hormone therapy for patients with Prosigna high ROR test results (>60), versus hormone therapy alone for patients with Prosigna low ROR test results (≤60). All premenopausal women were required to have ovarian function suppression.

(Press release, Veracyte, MAY 29, 2026, View Source [SID1234666204])